In the framework of the Horizon 2020 project ESFR-SMART (2017-2021), the European Sodium Fast Reactor (ESFR) core was updated through a safety-related modification and optimization of the core design from the earlier FP7 CP-ESFR project (2009-2013). This study is dedicated to neutronic analyses of the improved ESFR core design. The conducted work is reported in two parts. Part I deals with the evaluation of the safety-related neutronic parameters of the fresh Beginning-of-Life (BOL) core carried out by 8 organizations using both continuous energy Monte Carlo and deterministic computer codes. In addition to the neutronics characterization of the core, a special emphasis was put on the calibration and verification of the computational tools involved in the analyses. Part II is devoted to once-through and realistic batch-wise burnup calculations aiming at the establishing of the equilibrium core state, which will later serve as a basis for detailed safety analyses.

In the framework of the Horizon 2020 project ESFR-SMART (2017-2021), the European Sodium Fast Reactor (ESFR) core was updated through a safety-related modification and optimization of the core design from the earlier FP7 CP-ESFR project (2009-2013). This study is dedicated to neutronic analyses of the improved ESFR core design. The conducted work is reported in two parts. Part I deals with the evaluation of the safety-related neutronic parameters of the fresh Beginning-of-Life (BOL) core carried out by 8 organizations using both continuous energy Monte Carlo and deterministic computer codes. In addition to the neutronics characterization of the core, a special emphasis was put on the calibration and verification of the computational tools involved in the analyses. Part II is devoted to once-through and realistic batch-wise burnup calculations aiming at the establishing of the equilibrium core state, which will later serve as a basis for detailed safety analyses.

The Horizon 2020 ESFR-SMART project investigates the behaviour of the commercial-size European Sodium-cooled Fast Reactor (ESFR) throughout its lifetime. This paper reports work focused on the End of Equilibrium Cycle (EOEC) loading of the ESFR, including neutronic analysis, core- and zone-wise reactivity coefficients, and more detailed local mapping of important safety-relevant parameters. Sensitivity and uncertainty analysis on these parameters have also been performed and a detailed investigation into decay heat mapping carried out. Due to the scope of this work the results have been split into three papers. The nominal operating conditions and both zone-wise and local mapping of reactivity coefficients are considered in this paper; the sensitivity and uncertainty analysis are detailed in Margulis et al. [1]; and the decay heat mapping calculations are reported in Jimenez-Carrascosa et al. [2]. The work was performed across four institutions using both continuous-energy Monte Carlo and deterministic reactor physics codes. A good agreement is observed between the methods, verifying the suitability of these codes for simulation of large, complicated reactor configurations; and giving confidence in the results for the most limiting ESFR EOEC core state for safety analysis. The results from this work will serve as basis for the transient calculations planned for the next stage of work on the ESFR, allowing for more in-depth studies to be performed on the multiphysics behaviour of the reactor.

Background:In February of 2009 the Canarian registry of chronic myeloid leukemia (CML) was created in order get a better insight of treatment response, behavior and outcome in our region. For that purpose data from patients (pts) treated in the 7 hospitals of the Canary Islands was collected.Aims:Analyze Overall survival and responses to the tyrosine kinase inhibitor (TKI) treatment on real life CP‐CML pts.Methods:Our series consisted of 262 pts with CP‐CML diagnosed between 2000 and 2019 and treated with TKIs, 138 (52.7%) were males and 124 (47.3%) females with a mean age at diagnosis of 52.66 ± 17.36. The median follow‐up for the whole series is 6.26 years (0.02‐19.21). We analyzed overall survival (OS), cumulative incidence (CI) of major molecular response (MMR) and deep molecular response (DMR) on 2 first lines with Kaplan‐Meier test (KM) and compared the molecular response of different treatments on first and second line of treatment using the Jonckheere‐Terpstra test (JT). For the statistics we used SPSS V.23 and the p‐value was 0.05.Results:We have an OS at 8 years of 88.8%. Totally 39 pts died from which 3 (7.7%) were clinically related to CML. 183 (69.85%) pts received only 1 line of treatment, 55 (20.99%) 2 lines of treatment, 16 (6.1%) 3 lines of treatment and 8 (3.05%) 4 or more lines of treatment. At this moment 87 (39.01%) pts are on Imatinib (IM), 63 (28.25%) on Nilotinib (NI), 34 (15.25%) on Dasatinib (DA), 3 (1.35%) on Bosutinib, 2 (0.89%) on Ponatinib and 30 (13.45%) on Treatment free remission (TFR). All pts on TFR are on DMR with a median follow up of 6 months (0.5‐64). 172 (77.13%) pts are on DMR, 30 (13.45%) pts are on MMR, 9 (4.03%) pts are on cytogenetic response, 10 (4.45%) pts are on complete hematologic response and only 2 (0.89%) did not achieve any response.In 1st line 193 (86.54%) pts were treated with IM, 51 (22.87%) with NI and 18 (8.07%) with DA. By the JT test we found that there is a statistically significant difference between the medians of BCR/ABL levels at 3 (IM = 1.00, NI = 0.06, DA = 0.14), 6 (IM = 0.06, NI = 0.003, DA = 0.021) and 12 (IM = 0.014, NI = 0.0006, DA = 0.022) months between the different drugs (p < 0.001). We also found statistically significant difference for the CI of MMR between NI and IM (p < 0.001) and between NI and DA (p = 0.029) with a median of time till MMR of 3.27 months NI, 9.53 for IM and 7.9 for DA (Fig1a). We found a statistically significant difference for the CI of DMR between IM and NI (p = 0.004) with a median of time till DMR of 23.33 months for DA, 19.8 for IM and 11.2 for NI.We treated 79 pts with a TKI in 2nd line with a median follow‐up of 4.34 years (0‐11.37). 3 (73.66%) pts were treated with IM, 52 (19.47%) with NI and 24 (6.87%) with DA. By the JT test we found no statistically significant difference between the medians of BCR/ABL levels at 3 (IM = 0.14, NI = 0.02, DA = 0.10), 6 (IM = 1.00, NI = 0.06, DA = 0.00) and 12 (IM = 0.04, NI = 0.01, DA = 0.00) months between the different drugs (p = 0.979, p = 0.31 and p = 0.54 respectively). There is no statistically significant difference for the CI of MMR between the three treatment groups with a median of time till MMR of 5.13 months NI, 4.3 for IM and 6.7 for DA (Fig1b).Summary/Conclusion:Our OS is comparable to the one presented on the IRIS study 8‐year follow‐up (85%). When we analyzed the responses on 1st line we found that NI reaches faster the MMR than IM and DA. We also found differences reaching DMR between NI and IM but no with DA and we think the reason for not finding it is due to the small sample of pts with DA. The differences between 2nd generation TKIs are not present on 2nd line.image

No abstract